Organon & Co. (OGN)
USD 9.59
(1.48%)
USD 9.59
(1.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.26 Billion USD | 1.44% |
| 2022 | 6.17 Billion USD | -2.06% |
| 2021 | 6.3 Billion USD | -22.13% |
| 2020 | 8.09 Billion USD | 4.1% |
| 2019 | 7.77 Billion USD | -20.46% |
| 2018 | 9.77 Billion USD | -6.89% |
| 2017 | 10.5 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.58 Billion USD | -1.56% |
| 2024 Q2 | 1.6 Billion USD | -0.92% |
| 2024 Q1 | 1.62 Billion USD | 1.5% |
| 2023 Q1 | 1.53 Billion USD | 3.57% |
| 2023 Q3 | 1.51 Billion USD | -5.53% |
| 2023 Q2 | 1.6 Billion USD | 4.55% |
| 2023 Q4 | 1.59 Billion USD | 5.2% |
| 2023 FY | 6.26 Billion USD | 1.44% |
| 2022 Q1 | 1.56 Billion USD | -2.31% |
| 2022 FY | 6.17 Billion USD | -2.06% |
| 2022 Q4 | 1.48 Billion USD | -3.38% |
| 2022 Q3 | 1.53 Billion USD | -3.03% |
| 2022 Q2 | 1.58 Billion USD | 1.15% |
| 2021 Q2 | 1.59 Billion USD | 5.91% |
| 2021 FY | 6.3 Billion USD | -22.13% |
| 2021 Q1 | 1.5 Billion USD | -52.6% |
| 2021 Q4 | 1.6 Billion USD | 0.25% |
| 2021 Q3 | 1.6 Billion USD | 0.31% |
| 2020 Q4 | 3.17 Billion USD | 96.96% |
| 2020 Q3 | 1.61 Billion USD | 5.7% |
| 2020 Q2 | 1.52 Billion USD | -14.27% |
| 2020 Q1 | 1.78 Billion USD | 0.0% |
| 2020 FY | 8.09 Billion USD | 4.1% |
| 2019 FY | 7.77 Billion USD | -20.46% |
| 2018 FY | 9.77 Billion USD | -6.89% |
| 2017 FY | 10.5 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AbbVie Inc. | 54.31 Billion USD | 88.47% |
| Bristol-Myers Squibb Company | 45 Billion USD | 86.084% |
| Bristol-Myers Squibb Company Ce | 45 Billion USD | 86.084% |
| Johnson & Johnson | 85.15 Billion USD | 92.646% |
| Eli Lilly and Company | 34.12 Billion USD | 81.646% |
| Merck & Co., Inc. | 60.11 Billion USD | 89.582% |
| Novartis AG | 46.66 Billion USD | 86.577% |
| Pfizer Inc. | 58.49 Billion USD | 89.293% |